EMA SAYS EMA WILL ASSESS BENEFITS AND RISKS OF PAXLOVID UNDER A REDUCED TIMELINE AND COULD ISSUE AN OPINION WITHIN WEEKS
Ema Says Ema Will Assess Benefits And Risks Of Paxlovid Under A Reduced Timeline And Could Issue An Opinion Within Weeks
![Reuters logo](/images/reuters.jpg)
EMA SAYS EMA WILL ASSESS BENEFITS AND RISKS OF PAXLOVID UNDER A REDUCED TIMELINE AND COULD ISSUE AN OPINION WITHIN WEEKS